Cancer Diagnostics – Multimedia

Download this eBook to learn more about the impact of methylation and epigenetics in cancer.

Researchers at the Bruker-MUSC Clinical Glycomics Center of Excellence are developing and applying new technologies to map glycans in tissue and classify changes that occur during development of cancer.

Liquid biopsies are rapidly gaining traction and becoming a standard of care for cancer. They are an attractive alternative to invasive, painful, costly tissue biopsies and can facilitate real-time monitoring while providing insight into the disease state, even for tissues that are difficult to access, such as brain cancers.

With recent advances in cancer detection and prevention, a future where cancer can be cured is starting to feel within reach. One significant area of progress is early detection, which can go a long way toward eliminating cancer.

Agilent sample quality metrics are available for most RNA and DNA samples used in NGS, enabling you to know the concentration, size and integrity of your nucleic acid fragments.

Since many cancers don’t have symptoms early on, they may go unnoticed until they are at an advanced stage. But that is changing, thanks to a newer, non-invasive tool.

Download this listicle to explore various biomarkers, technological advances driving biomarker research and integrative approaches in disease research.

Next-generation sequencing (NGS) is an essential tool in molecular biology laboratories for the analysis of nucleic acid samples in numerous basic, translational and clinical research settings. Download this app compendium to discover systems that can be used to analyze genomic DNA, cell-free DNA, total RNA.

For circulating cell free DNA (ccfDNA) to be used in cancer research successfully, workflow standardization is essential. Access this poster to discover tips on optimal workflow control, how to yield smaller ccfDNA fragments and the differences in quantification and qualification of ccfDNA.

Urinalysis has long been a staple of physical exams to detect and manage a number of diseases and disorders, but not cancer. What if it were that easy, though, and cancer was detected in its very earliest stages when the disease responds more favorably to treatment and improved outcomes are more likely?